How to use macrophages to realise the treatment of tumour

References

• Batrakova EV, Li S, Reynolds AD, et al. A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem. 2007;18(5):1498–1506.
   PubMed Web of Science ®Google Scholar
• Alizadeh D, Zhang L, Hwang J, et al. Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas. Nanomedicine. 2010;6(2):382–390.
   PubMed Web of Science ®Google Scholar
• Spill F, Reynolds DS, Kamm RD, et al. Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 2016;40:41–48.
   PubMed Web of Science ®Google Scholar
• Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16(7):447–462.
   PubMed Web of Science ®Google Scholar
• Liu D, Lu Q, Wang X, et al. LSECtin on tumor-associated macrophages enhances breast cancer stemness via interaction with its receptor BTN3A3. Cell Res. 2019;29(5):365–378.
   PubMed Web of Science ®Google Scholar
• Laoui D, Van Overmeire E, Di Conza G, et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 2014;74(1):24–30.
   PubMed Web of Science ®Google Scholar
• Stone SC, Rossetti RAM, Alvarez KLF, et al. Lactate secreted by cervical cancer cells modulates macrophage phenotype. J Leukoc Biol. 2019;105(5):1041–1054.
   PubMed Web of Science ®Google Scholar
• Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol. 2012;32(6):463–488.
   PubMed Web of Science ®Google Scholar
• Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496(7446):445–455.
   PubMed Web of Science ®Google Scholar
• Stow JL, Condon ND. The cell surface environment for pathogen recognition and entry. Clin Transl Immunol. 2016;5(4):e71.
   PubMedGoogle Scholar
• Owen JL, Mohamadzadeh M. Macrophages and chemokines as mediators of angiogenesis. Front Physiol. 2013;4:159–158.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.
   PubMed Web of Science ®Google Scholar
• Ostuni R, Kratochvill F, Murray PJ, et al. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015;36(4):229–239.
   PubMed Web of Science ®Google Scholar
• Hayes BH, Tsai RK, Dooling LJ, et al. Macrophages show higher levels of engulfment after disruption of cis interactions between CD47 and the checkpoint receptor SIRPα. J Cell Sci. 2020;133(5):jcs237800.
   PubMed Web of Science ®Google Scholar
• Lee C, Jeong H, Bae Y, et al. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. J Immunother Cancer. 2019;7(1):147.
   PubMedGoogle Scholar
• Jeannin P, Paolini L, Adam C, et al. The roles of CSFs on the functional polarization of tumor-associated macrophages. Febs J. 2018;285(4):680–699.
   PubMed Web of Science ®Google Scholar
• Iriki T, Ohnishi K, Fujiwara Y, et al. The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation. Lung Cancer. 2017;106:22–32.
   PubMed Web of Science ®Google Scholar
• Shree T, Olson OC, Elie BT, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011;25(23):2465–2479.
   PubMed Web of Science ®Google Scholar
• Halbrook CJ, Pontious C, Kovalenko I, et al. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metab. 2019;29(6):1390–1399.e6.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang J, Zhang M, et al. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients. Breast Cancer Res Treat. 2017;166(1):95–107.
   PubMed Web of Science ®Google Scholar
• Cavnar MJ, Zeng S, Kim TS, et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med. 2013;210(13):2873–2886.
   PubMed Web of Science ®Google Scholar
• Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36(1):53.
   PubMed Web of Science ®Google Scholar
• Arlauckas SP, Garris CS, Kohler RH, et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 2017;9(389):eaal3604.
   PubMed Web of Science ®Google Scholar
• Morandi F, Pistoia V. Interactions between HLA-G and HLA-E in physiological and pathological conditions. Front Immunol. 2014;5:394.
   PubMed Web of Science ®Google Scholar
• Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med. 2015; 12(2):74–78.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016; 39(1):98–106.
   PubMed Web of Science ®Google Scholar
• Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kγ is a molecular switch that controls immune suppression. Nature. 2016;539(7629):437–442.
   PubMed Web of Science ®Google Scholar
• Belgiovine C, Bello E, Liguori M, et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017;117(5):628–638.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Sporn MB. The war on cancer. Lancet. 1996;347(9012):1377–1381.
   PubMed Web of Science ®Google Scholar
• Korolev KS, Xavier JB, Gore J. Turning ecology and evolution against cancer. Nat Rev Cancer. 2014;14(5):371–380.
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–1564.
   PubMed Web of Science ®Google Scholar
• Peng M, Deng J, Zhou S, et al. The role of clusterin in cancer metastasis. Cancer Manag Res. 2019;11:2405–2414.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang X, Li X, et al. Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells. Oncol Rep. 2018;39(2):818–826.
   PubMed Web of Science ®Google Scholar
• Zeng XY, Xie H, Yuan J, et al. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. Cancer Biol Ther. 2019;20(7):956–966.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang S, Wang Q, et al. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. 2017;10(1):36.
   PubMedGoogle Scholar
• Sanchez LR, Borriello L, Entenberg D, et al. The emerging roles of macrophages in cancer metastasis and response to chemotherapy. J Leukoc Biol. 2019;106(2):259–274.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.
   PubMed Web of Science ®Google Scholar
• Lan J, Sun L, Xu F, et al. M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer. Cancer Res. 2019;79(1):146–158.
   PubMed Web of Science ®Google Scholar
• Sas-Chen A, Aure MR, Leibovich L, et al. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Mol Med. 2016;8(9):1052–1064.
   PubMed Web of Science ®Google Scholar
• Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887–904.
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Lewis CE, Naldini L, et al. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol. 2010;176(4):1564–1576.
   PubMed Web of Science ®Google Scholar
• Zhang J, Patel L, Pienta KJ. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci. 2010;95:31–53.
   PubMed Web of Science ®Google Scholar
• Brana I, Calles A, LoRusso PM, et al. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015;10(1):111–123.
   PubMed Web of Science ®Google Scholar
• Chambers SEJ, O'Neill CL, O'Doherty TM, et al. The role of immune-related myeloid cells in angiogenesis. Immunobiology. 2013;218(11):1370–1375.
   PubMed Web of Science ®Google Scholar
• Siveen KS, Prabhu K, Krishnankutty R, et al. Vascular endothelial growth factor (VEGF) signaling in tumour vascularization: potential and challenges. Curr Vasc Pharmacol. 2017;15(4):339–351.
   PubMed Web of Science ®Google Scholar
• Linde N, Lederle W, Depner S, et al. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J Pathol. 2012;227(1):17–28.
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Fukushi J, Yamamoto S, et al. Macrophage infiltration predicts a poor prognosis for human Ewing sarcoma. Am J Pathol. 2011;179(3):1157–1170.
   PubMed Web of Science ®Google Scholar
• Banciu M, Metselaar JM, Schiffelers RM, et al. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia. 2008;10(2):108–117.
   PubMed Web of Science ®Google Scholar
• Rogers TL, Wind N, Hughes R, et al. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models. Cell Oncol (Dordr)). 2013;36(6):505–514.
   PubMed Web of Science ®Google Scholar
• Galmbacher K, Heisig M, Hotz C, et al. Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. PLoS One. 2010;5(3):e9572.
   PubMed Web of Science ®Google Scholar
• Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer. 2016;2(1):15025.
   PubMedGoogle Scholar
• Wyckoff JB, Wang Y, Lin EY, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649–2656.
   PubMed Web of Science ®Google Scholar
• Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013;93(6):847–863.
   PubMed Web of Science ®Google Scholar
• Guerriero JL, Sotayo A, Ponichtera HE, et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017;543(7645):428–432.
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhang Z, Jiang Y, et al. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J Control Release. 2012;158(2):286–292.
   PubMed Web of Science ®Google Scholar
• Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011;19(1):31–44.
   PubMed Web of Science ®Google Scholar
• Hoves S, Ooi CH, Wolter C, et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J Exp Med. 2018;215(3):859–876.
   PubMed Web of Science ®Google Scholar
• Perry CJ, Muñoz-Rojas AR, Meeth KM, et al. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med. 2018;215(3):877–893.
   PubMed Web of Science ®Google Scholar
• Noel M, O’Reilly EM, Wolpin BM, et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif)receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020;38(3):800–811.
   PubMed Web of Science ®Google Scholar
• Zollo M, Di Dato V, Spano D, et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis. 2012;29(6):585–601.
   PubMed Web of Science ®Google Scholar
• Wesolowski R, Sharma N, Reebel L, et al. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 2019;11:1758835919854238.
   Web of Science ®Google Scholar
• Edwards VDK, Sweeney DT, Ho H, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 2018;9(37):24576–24589.
   PubMedGoogle Scholar
• von Tresckow B, Morschhauser F, Ribrag V, et al. An open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma. Clin Cancer Res. 2015;21(8):1843–1850.
   PubMed Web of Science ®Google Scholar
• Gomez-Roca CA, Italiano A, Le Tourneau C, et al. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann Oncol. 2019;30(8):1381–1392.
   PubMed Web of Science ®Google Scholar
• Sikic BI, Lakhani N, Patnaik A, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37(12):946–953.
   PubMed Web of Science ®Google Scholar
• Russ A, Hua AB, Montfort WR, et al. Blocking “don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review. Blood Rev. 2018;32(6):480–489.
   PubMed Web of Science ®Google Scholar
• Petrova PS, Viller NN, Wong M, et al. TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res. 2017;23(4):1068–1079.
   PubMed Web of Science ®Google Scholar
• Cabo M, Offringa R, Zitvogel L, et al. Trial watch: immunostimulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2017;6(12):e1371896.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Burg JM, Mick R, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2(1):e23033.
   PubMed Web of Science ®Google Scholar
• Adams S, Kozhaya L, Martiniuk F, et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res. 2012;18(24):6748–6757.
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Cooley S, DeFor T, et al. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. Am J Hematol. 2012;87(10):953–956.
   PubMed Web of Science ®Google Scholar
• Smith DA, Conkling P, Richards DA, et al. Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunol Immunother. 2014;63(8):787–796.
   PubMed Web of Science ®Google Scholar
• Lobera M, Madauss KP, Pohlhaus DT, et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013;9(5):319–325.
   PubMed Web of Science ®Google Scholar
• Li WJ, Tang XF, Shuai XX, et al. Mannose receptor mediates the immune response to ganoderma atrum polysaccharides in macrophages. J Agric Food Chem. 2017;65(2):348–357.
   PubMed Web of Science ®Google Scholar
• Yi BG, Park OK, Jeong MS, et al. In vitro photodynamic effects of scavenger receptor targeted-photoactivatable nanoagents on activated macrophages. Int J Biol Macromol. 2017;97:181–189.
   PubMed Web of Science ®Google Scholar
• Holden JA, O'Brien-Simpson NM, Lenzo JC, et al. Porphyromonas gulae activates unprimed and gamma interferon-primed macrophages via the pattern recognition receptors toll-like receptor 2 (TLR2), TLR4, and NOD2. Infect Immun. 2017;85(9):17.
   Web of Science ®Google Scholar
• Challa DK, Wang X, Montoyo HP, et al. Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis. MAbs. 2019;11(5):848–860.
   PubMed Web of Science ®Google Scholar
• Little AC, Pathanjeli P, Wu Z, et al. IL-4/IL-13 stimulated macrophages enhance breast cancer invasion via Rho-GTPase regulation of synergistic VEGF/CCL-18 signaling. Front Oncol. 2019;9:456.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee E, Ko E, et al. Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9. Cancer Lett. 2018;437:25–34.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555.
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332–337.
   PubMed Web of Science ®Google Scholar
• Verreck FA, de Boer T, Langenberg DM, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA. 2004;101(13):4560–4565.
   PubMed Web of Science ®Google Scholar
• Jin R, Liu L, Zhu W, et al. Iron oxide nanoparticles promote macrophage autophagy and inflammatory response through activation of toll-like Receptor-4 signaling. Biomaterials. 2019;203:23–30.
   PubMed Web of Science ®Google Scholar
• Wang H, Shrestha TB, Basel MT, et al. Magnetic-Fe/Fe(3)O(4)-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages. Beilstein J Nanotechnol. 2012;3:444–455.
   PubMed Web of Science ®Google Scholar
• Basel MT, Balivada S, Shrestha TB, et al. A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model. Small. 2012;8(6):913–920.
   PubMed Web of Science ®Google Scholar
• Choi MR, Stanton-Maxey KJ, Stanley JK, et al. A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 2007;7(12):3759–3765.
   PubMed Web of Science ®Google Scholar
• Holden CA, Yuan Q, Yeudall WA, et al. Surface engineering of macrophages with nanoparticles to generate a cell-nanoparticle hybrid vehicle for hypoxia-targeted drug delivery. Int J Nanomed. 2010;5:25–36.
   PubMed Web of Science ®Google Scholar
• Basel MT, Balivada S, Wang H, Shrestha TB, et al. Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model. Int J Nanomed. 2012;7:297–306.
   PubMed Web of Science ®Google Scholar
• Choi J, Kim HY, Ju EJ, et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials. 2012;33(16):4195–4203.
   PubMed Web of Science ®Google Scholar
• Fu J, Wang D, Mei D, et al. Macrophage mediated biomimetic delivery system for the treatment of lung metastasis of breast cancer. J Control Release. 2015;204:11–19.
   PubMed Web of Science ®Google Scholar
• Qiang L, Cai Z, Jiang W, et al. A novel macrophage-mediated biomimetic delivery system with NIR-triggered release for prostate cancer therapy. J Nanobiotechnol. 2019;17(1):83.
   PubMedGoogle Scholar
• Zhang W, Wang M, Tang W, et al. Nanoparticle-laden macrophages for tumor-tropic drug delivery. Adv Mater Weinheim. 2018;30(50):e1805557.
   PubMed Web of Science ®Google Scholar
• Chen F, Chen J, Yang L, et al. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol. 2019;21(4):498–510.
   PubMed Web of Science ®Google Scholar
• Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–345.
   PubMed Web of Science ®Google Scholar
• Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015;207:18–30.
   PubMed Web of Science ®Google Scholar
• Schindler C, Collinson A, Matthews C, et al. Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency. PLoS One. 2019;14(3):e0214545.
   PubMed Web of Science ®Google Scholar
• Haney MJ, Zhao Y, Jin YS, et al. Macrophage-derived extracellular vesicles as drug delivery systems for triple negative breast cancer (TNBC) therapy. J Neuroimmune Pharmacol. 2019. DOI:10.1007/s11481-019-09884-19. [published online ahead of print].
   PubMed Web of Science ®Google Scholar
• Montecalvo A, Larregina AT, Shufesky WJ, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2012;119(3):756–766.
   PubMed Web of Science ®Google Scholar
• Kim MS, Haney MJ, Zhao Y, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016;12(3):655–664.
   PubMed Web of Science ®Google Scholar
• Kim MS, Haney MJ, Zhao Y, et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2018;14(1):195–204.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cai K, Li C, et al. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy. Nano Lett. 2018;18(3):1908–1915.
   PubMed Web of Science ®Google Scholar
• Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11(11):762–774.
   PubMed Web of Science ®Google Scholar
• Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344(6186):921–925.
   PubMed Web of Science ®Google Scholar
• Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–964.
   PubMed Web of Science ®Google Scholar
• Kumar P, Bose PP. Macrophage ghost entrapped amphotericin B: a novel delivery strategy towards experimental visceral leishmaniasis. Drug Deliv Transl Res. 2019;9(1):249–259.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Gendelman HE, Kabanov AV. Cell-mediated drug delivery. Expert Opin Drug Deliv. 2011;8(4):415–433.
   PubMed Web of Science ®Google Scholar
• Kelly PM, Davison RS, Bliss E, et al. Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer. 1988;57(2):174–177.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J Control Release. 2014;190:531–541.
   PubMed Web of Science ®Google Scholar
• Xuan M, Shao J, Dai L, et al. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Healthc Mater. 2015;4(11):1645–1652.
   PubMed Web of Science ®Google Scholar
• Liu R, An Y, Jia W, et al. Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer. J Control Release. 2020;321:589–601.
   PubMed Web of Science ®Google Scholar
• Cao X, Tan T, Zhu D, et al. Paclitaxel-loaded macrophage membrane camouflaged albumin nanoparticles for targeted cancer therapy. Int J Nanomed. 2020;15:1915–1928.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Ghosh SS. Transmembrane TNFα-expressed macrophage membrane-coated chitosan nanoparticles as cancer therapeutics. ACS Omega. 2020;5(3):1572–1580.
   PubMed Web of Science ®Google Scholar
• Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904.
   PubMed Web of Science ®Google Scholar
• Cao H, Dan Z, He X, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano. 2016;10(8):7738–7748.
   PubMed Web of Science ®Google Scholar
• Li Y, Yan T, Chang W, et al. Fabricating an intelligent cell-like nanoprodrug via hierarchical self-assembly based on the DNA skeleton for suppressing lung metastasis of breast cancer. Biomater Sci. 2019;7(9):3652–3366.
   PubMed Web of Science ®Google Scholar
• Sun K, Yu W, Ji B, et al. Saikosaponin D loaded macrophage membrane-biomimetic nanoparticles target angiogenic signaling for breast cancer therapy. Appl Mater Today. 2020;18:100505.
   Web of Science ®Google Scholar
• Chen W, Zeng K, Liu H, et al. Cell membrane camouflaged hollow Prussian blue nanoparticles for synergistic photothermal-/chemotherapy of cancer. Adv Funct Mater. 2017;27(11):1605795.
   Web of Science ®Google Scholar
• Zheng T, Li GG, Zhou F, et al. Gold-nanosponge-based multistimuli-responsive drug vehicles for targeted chemo-photothermal therapy. Adv Mater Weinheim. 2016;28(37):8218–8226.
   PubMed Web of Science ®Google Scholar
• Cheng L, Wang C, Feng L, et al. Functional nanomaterials for phototherapies of cancer. Chem Rev. 2014;114(21):10869–10939.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gong X. Superhydrophobic coatings with periodic ring structured patterns for self-cleaning and oil-water separation. Adv Mater Interfaces. 2017;4(16):1700190.
   Web of Science ®Google Scholar
• Liu Z, Davis C, Cai W, et al. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci USA. 2008;105(5):1410–1415.
   PubMed Web of Science ®Google Scholar
• Rao L, Xu JH, Cai B, et al. Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake. Nanotechnology. 2016;27(8):085106.
   PubMed Web of Science ®Google Scholar
• Meng QF, Rao L, Zan M, et al. Macrophage membrane-coated iron oxide nanoparticles for enhanced photothermal tumor therapy. Nanotechnology. 2018;29(13):134004.
   PubMed Web of Science ®Google Scholar
• Yang S, Li Z, Wang Y, et al. Multifunctional Bi@PPy-PEG core-shell nanohybrids for dual-modal imaging and photothermal therapy. ACS Appl Mater Interfaces. 2018;10(2):1605–1615.
   PubMed Web of Science ®Google Scholar
• Yu N, Wang Z, Zhang J, et al. Thiol-capped bi nanoparticles as stable and all-in-one type theranostic nanoagents for tumor imaging and thermoradiotherapy. Biomaterials. 2018;161:279–291.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li L, Zhang J, et al. C-C chemokine ligand 2 (CCL2) recruits macrophage-membrane-camouflaged hollow bismuth selenide nanoparticles to facilitate photothermal sensitivity and inhibit lung metastasis of breast cancer. ACS Appl Mater Interfaces. 2018;10(37):31124–31135.
   PubMed Web of Science ®Google Scholar
• Xuan M, Shao J, Dai L, et al. Macrophage cell membrane camouflaged Au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces. 2016;8(15):9610–9618.
   PubMed Web of Science ®Google Scholar
• Liao X, Shen Y, Zhang R, et al. Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy. Proc Natl Acad Sci USA. 2018;115(20):E4661–E4669.
   PubMed Web of Science ®Google Scholar
• Minutti CM, Jackson-Jones LH, García-Fojeda B, et al. Local amplifiers of IL-4Rα-mediated macrophage activation promote repair in lung and liver. Science. 2017;356(6342):1076–1080.
   PubMed Web of Science ®Google Scholar
• Bosurgi L, Cao YG, Cabeza-Cabrerizo M, et al. Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. Science. 2017;356(6342):1072–1076.
   PubMed Web of Science ®Google Scholar
• Thamphiwatana S, Angsantikul P, Escajadillo T, et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc Natl Acad Sci USA. 2017;114(43):11488–11493.
   PubMed Web of Science ®Google Scholar